Molecular Staging Molecular Staging is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.
  • Molecular Staging Completes $41.25 Million Private Financing

    Funding will enhance Molecular Staging’s leadership position in signal and target amplification and accelerate MSI’s efforts in the proteomics, genomics and molecular diagnostics markets.

    NEW HAVEN, CT — Molecular Staging Inc. (MSI), a privately-held life sciences tool company, announced today that it has completed a Series D preferred stock financing totaling $41.25 million. Investor AB, through Investor Growth Capital, participated in the private placement along with OrbiMed, CIBC Capital Partners and Cooper Hill Partners. Domain Partners III, CHL Medical Partners and 3i Bioscience Investment Trust, who were already holders of preferred stock in Molecular Staging, also participated in the new round of financing. Investor AB and OrbiMed will be entitled to name two representatives to the board.

    Liza Page Nelson, Managing Director of Investor Growth Capital said “Molecular Staging has made tremendous progress in the development and validation of its key platforms. Seldom does one find a company whose technology can broadly address so many markets; these include research reagents, drug research and development, diagnostics, and life sciences.”

    “Naturally we are extremely pleased to have achieved this financial milestone, and it is especially gratifying to have our original investors, Domain Associates, CHL Medical Partners, and 3i Bio science Investment Trust increase their ownership stake in Molecular Staging” said Torben Christensen, President and Chief Executive Officer of Molecular Staging. Stephen Kingsmore, M.D., Chief Operating Officer of Molecular Staging added “We have successfully completed the research required to prove the validity and utility of our technology. The additional funding will support our on-going efforts to expand our technology base as well as to develop products and services for our customers and partners.”

    Molecular Staging Inc. is a private, life sciences tool company developing a portfolio of technologies for the detection and measurement of proteins and nucleic acids across a broad range of applications, including proteomics, genomics, pharmacogenomics and diagnostics. MSI’s core technology is Rolling Circle Amplification Technology (RCAT™), an isothermal amplification process for detecting and measuring all classes of biomolecules including protein, DNA, and RNA. RCAT™ has significant advantages in dynamic range, scalability, sensitivity, multiplexing and flexibility over older methods, such as PCR. RCAT™ is the only molecular amplification method that allows target recognition, signal amplification, and detection all to be performed directly on a microarray. The technology is compatible with many existing instrument platforms and is ideally suited for multiplexing assays in liquid and solid phase and direct amplification in cells and tissues. MSI is located in New Haven, Connecticut. Additional information about MSI can be found at www.molecularstaging.com.

    This press release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company’s actual results may differ materially from the Company’s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company’s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, ability to hire required personnel, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other potential factors.

    Published on October 11, 2012 · Filed under: Press Release;
    Comments Off on Molecular Staging Completes $41.25 Million Private Financing